Revival of Bispecific Antibodies: The Way Forward?
Sheraton Boston Hotel

Boston, Massachusetts


   The interest in bispecific and multivalent antibodies has been renewed
   because of advances that now allow them to be manufactured in a stable
   and reliable manner. This has opened up the field to a multitude of
   approaches for creating bispecific antibodies against a variety of
   targets. The decision-making process about when a bispecific or
   multiclonal approach should be used, and what mechanism is likely to
   be the most effective against a given indication, will be discussed.
   This format will allow for ample interaction amongst participants so
   they can learn new techniques from each other and add to their arsenal
   of options, and find out what might work best in their own lab.

Schedule of Presentations:

Thursday, May 20, 2010
12:00:00 Registration
13:25:00 SELECTION CRITERIA FOR BISPECIFIC ANTIBODIES: How Do You Decide When to Use Them and which Is a Better Choice?
13:30:00 Chairperson’s Opening Remarks Patrick Baeuerle
13:40:00 FEATURED PRESENTATION - Bispecific Antibodies: Developments and Current Perspectives Roland Kontermann
14:10:00 Single Chain Immunoglobulins – A New Way to Generate Bispecific Antibodies Thomas Schirrmann
14:40:00 Sponsored Presentations (Opportunities Available)
15:10:00 Networking Refreshment Break, Poster and Exhibit Viewing
16:00:00 Efficient Chemical Approaches to Bispecific Antibodies and Antibodies of High Valency Carlos F. Barbas III
16:30:00 Chimeric Antigen Receptors Arm T-Cells to Fight Cancer Hinrich J. Abken
17:00:00 Problem-Solving Break-Out Discussions
17:15:00 Challenges in Developing Bispecific Antibodies Nazzareno Dimasi
17:30:00 Targeting Stem Cells with Bispecific Antibodies Lawrence G. Lum
17:45:00 Bispecific Antibodies for Tumor Therapy Roland Kontermann
18:00:00 End of Day
Friday, May 21, 2010
07:45:00 Continental Breakfast in the Exhibit Hall
08:25:00 CREATING A BISPECIFIC – A Variety of Approaches
08:30:00 Chairperson’s Opening Remarks Michael J. Feldhaus
08:35:00 Strand Exchange Engineered Domain (SEED), a Protein Engineering Strategy Designed to Create a Heterodimer Protein Scaffold Marco Muda
09:05:00 Engineering Antibodies to Concurrently Target Multiple Disease Mediators Nazzareno Dimasi
09:35:00 bis-Fabs: A New Platform for Bispecific Molecules Justin M. Scheer
10:05:00 Coffee Break, Poster and Exhibit Viewing
11:05:00 Trifunctional Antibodies: What’s So different? Horst Lindhofer
11:35:00 Combining mABs and dABs: Generation of Dual-Targeting Antibodies and Their Preclinical Development Paul Hamblin
12:05:00 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own
13:25:00 Chairperson’s Remarks Aaron K. Sato
13:30:00 Bispecific Antibodies for Effective Engagement of T Cells in Cancer Therapy Patrick Baeuerle
14:00:00 Catumaxomab (Removab): The First Approved Bispecific, Trifunctional Antibody Diane Seimetz
14:30:00 Networking Refreshment Break
15:00:00 CVX-241 - A Bispecific Covx-Body Targeting Angiogenesis Gary Woodnutt
15:30:00 mAb2: Novel Bispecific Antibodies that are Minimally Changed from IgG Kevin FitzGerald
16:00:00 Targeting T Cells to Tumors and Stem Cells for Myocardial Repair with Bispecific Antibodies Lawrence G. Lum
16:30:00 End of Conference
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.